Search - tctmd.com

Displaying 241 - 260 of 492

Sort: Relevancy | Date

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

News Daily News

Cardio-Obstetrics Merits Better Training, Wider Uptake: Survey

Caitlin E. Cox

April 26, 2022

News Daily News

Don’t Rule Out CABG for Elderly Patients With Multiple Comorbidities

Michael O'Riordan

April 25, 2022

News Daily News

CVD Hospitalizations Spiked in Aftermath of 2020 US Election

Michael O'Riordan

April 22, 2022

News Daily News

Myocarditis Risk Varies Among mRNA-Based COVID-19 Vaccines

Todd Neale

April 21, 2022

News Conference News ACC 2022

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

Michael O'Riordan

April 13, 2022

News Conference News ACC 2022

DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF

L.A. McKeown

April 08, 2022

News Conference News ACC 2022

PROMPT-HF: Pop-up Alerts Improve HFrEF Medication Optimization

L.A. McKeown

April 03, 2022

News Conference News ACC 2022

CHAP: Better Blood Pressure Control, Better Pregnancy Outcomes

Michael O'Riordan

April 02, 2022

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Shelley Wood

April 01, 2022

News Opinion CV Team Dispatch

April 2022 News Roundup

L.A. McKeown

April 01, 2022

News Daily News

Myocarditis Risk Remains Rare After Third mRNA Vaccine Dose

Todd Neale

March 23, 2022

News Daily News

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

L.A. McKeown

March 22, 2022

More Evidence Links Breast Arterial Calcification and CVD Risk

News Daily News

Guideline-Directed Therapies Underused in Frail HF Patients

L.A. McKeown

March 11, 2022

News Daily News

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

Michael O'Riordan

March 01, 2022

News Opinion CV Team Dispatch

March 2022 News Roundup

L.A. McKeown

March 01, 2022

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

News Daily News

Statin Intolerance Overestimated—Only ‘Small Number’ Get Side Effects: Meta-analysis

Michael O'Riordan

February 18, 2022

News Conference News THT 2022

Cardiogenic Shock’s Origins, Progression Tightly Tied to Mortality

Caitlin E. Cox

February 07, 2022

Advertisement

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Cardio-Obstetrics Merits Better Training, Wider Uptake: Survey

Don’t Rule Out CABG for Elderly Patients With Multiple Comorbidities

CVD Hospitalizations Spiked in Aftermath of 2020 US Election

Myocarditis Risk Varies Among mRNA-Based COVID-19 Vaccines

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF

PROMPT-HF: Pop-up Alerts Improve HFrEF Medication Optimization

CHAP: Better Blood Pressure Control, Better Pregnancy Outcomes

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

April 2022 News Roundup

Myocarditis Risk Remains Rare After Third mRNA Vaccine Dose

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

More Evidence Links Breast Arterial Calcification and CVD Risk

Guideline-Directed Therapies Underused in Frail HF Patients

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

March 2022 News Roundup

FDA Approves Empagliflozin for Treatment of HFpEF

Statin Intolerance Overestimated—Only ‘Small Number’ Get Side Effects: Meta-analysis

Cardiogenic Shock’s Origins, Progression Tightly Tied to Mortality

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content